Churg-Strauss syndrome

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 341-348

  Greco, Antonio ^a   Rizzo, Maria Ida ^b   De Virgilio, Armando ^a,b   Gallo, Andrea ^a   Fusconi, Massimo ^a   Ruoppolo, Giovanni ^a   Altissimi, Giancarlo ^a   De Vincentiis, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ANCA associated vasculitis; Asthma; Churg Strauss syndrome; Eosinophilic granulomatosis with polyangiitis; Hypereosinophilic syndromes; Wegener granulomatosis

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EOTAXIN 3; HLA DRB1 ANTIGEN; HLA DRB4 ANTIGEN; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OMALIZUMAB; RITUXIMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; ASTHMA; B LYMPHOCYTE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRONCHIECTASIS; CHRONIC KIDNEY FAILURE; CHRONIC SINUSITIS; CHURG STRAUSS SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM HEMORRHAGE; ECCHYMOSIS; ENVIRONMENTAL FACTOR; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC GRANULOMA; EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; ERYTHEMA; ERYTHEMA MULTIFORME; FACIAL NERVE PARALYSIS; FEVER; GLOMERULONEPHRITIS; GOLD STANDARD; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; HYPEREOSINOPHILIC SYNDROME; IMMUNOGENETICS; INTERSTITIAL NEPHRITIS; INTESTINE PERFORATION; LIVEDO RETICULARIS; MALAISE; MICROSCOPIC POLYANGIITIS; NOSE POLYP; OTITIS MEDIA; PATHOGENESIS; PERCEPTION DEAFNESS; PERICARDITIS; PERIPHERAL NEUROPATHY; PETECHIA; PREVALENCE; PROGNOSIS; PURPURA; PUSTULE; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHINOSINUSITIS; SMALL VESSEL VASCULITIS; SURVIVAL RATE; SYMPTOMATOLOGY; TH1 CELL; TH17 CELL; THORAX RADIOGRAPHY; UPREGULATION; URTICARIA; VALVULAR HEART DISEASE; WEIGHT REDUCTION; ANIMAL; CHURG-STRAUSS SYNDROME; COMPLICATION; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; RARE DISEASES;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ASTHMA; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RARE DISEASES;

EID: 84923105767     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.004     Document Type: Review

References (82)

1. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951, 27:277-301.
2. Jennette J., Falk R., Bacon P., Basu N., Cid M., Ferrario F., et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
3. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
4. Simon H.U., Rothenberg M.E., Bochner B.S., Weller P.F., Wardlaw A.J., Wechsler M.E., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
5. Valent P., Klion A.D., Horny H.P., Roufosse F., Gotlib J., Weller P.F., et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012, 130:607-612.
6. Kahn J.E., Bletry O., Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol 2008, 22:863-882.
7. Sinico R.A., Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009, 23:355-366.
8. Abril A., Calamia K.T., Cohen M.D. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 2003, 33:106-114.
9. Baldini C., Talarico R., Della Rossa A., Bombardieri R. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am 2010, 36:527-543.
10. Mahr A., Guillevin L., Poissonnet M., Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004, 51:92-99.
11. Piram M., Maldini C., Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 2012, 24:193-200.
12. Lane S.E., Watts R.A., Bentham G., Innes N.J., Scott D.G. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003, 48:814-823.
13. Ramentol-Sintas M., Martínez-Valle F., Solans-Laqué R. Churg-Strauss Syndrome: an evolving paradigm. Autoimmun Rev 2012, 12:235-240.
14. Cuchacovich R., Justiniano M., Espinoza L.R. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol 2007, 26:1769-1771.
15. Vaglio A., Martorana D., Maggiore U., Grasselli C., Zanetti A., Pesci A., et al. HLADRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007, 56:3159-3166.
16. Wieczorek S., Hellmich B., Gross W.L., Epplen J.T. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008, 58:329-330.
17. Kiene M., Csernok E., Muller A., Metzler C., Trabandt A., Gross W.L. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001, 44:469-473.
18. Jakiela B., Szczeklik W., Plutecka H., Sokolowska B., Mastalerz L., Sanak M., et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford) 2012, 51:1887-1893.
19. Jakiela B., Sanak M., Szczeklik W., Sokolowska B., Plutecka H., Mastalerz L., et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011, 29(1 Suppl 64):S23-S34.
20. Moosig F., Gross W.L., Herrmann K., Bremer J.P., Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011, 155:341-343.
21. Tsurikisawa N., Saito H., Tsuburai T., Oshikata C., Ono E., Mitomi H., et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008, 122:610-616.
22. Zwerina J., Bach C., Martorana D., Jatzwauk M., Hegasy G., Moosig F., et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) 2011, 50:1823-1827.
23. Polzer K., Karonitsch T., Neumann T., Eger G., Haberler C., Soleiman A., et al. Eotaxin-3 is involved in Churg-Strauss syndrome-a serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008, 47:804-808.
24. Terrier B., Bieche I., Maisonobe T., Laurendeau I., Rosenzwajg M., Kahn J.E., et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 2010, 116:4523-4531.
25. Radice A., Bianchi L., Sinico R.A. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev 2013, 12:487-495.
26. Hagen E.C., Daha M.R., Hermans J., Andrassy K., Csernok E., Gaskin G., et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998, 53:743-753.
27. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine 1999, 78:26-37.
28. Kallenberg C.G., Brouwer E., Weening J.J., Tervaert J.W. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994, 46:1-15.
29. Jennette J.C., Falk R.J. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008, 20:55-60.
30. Vaglio A., Strehl J.D., Manger B., Maritati F., Alberici F., Beyer C., et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2012, 71:390-393.
31. Sinico R.A., Di Toma L., Maggiore U., Bottero P., Radice A., Tosoni C., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935.
32. Sable-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005, 143:632-638.
33. Agmon-Levin N., Selmi C. The autoimmune side of heart and lung diseases. Clin Rev Allergy Immunol 2013, 44:1-5.
34. Vaglio A., Casazza I., Grasselli C., Corradi D., Sinico R.A., Buzio C. Churg-Strauss syndrome. Kidney Int 2009, 76:1006-1011.
35. Lanham J.G., Elkon K.B., Pusey C.D., Hughes G.R. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63:65-81.
36. Lhote F., Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 1995, 21:911-947.
37. Papadimitraki E.D., Kyrmizakis D.E., Kritikos I., Boumpas D.T. Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol 2004, 22:485-494.
38. Greco A., Fusconi M., Gallo A., Marinelli C., Macri G.F., De Vincentiis M. Sudden sensorineural hearing loss: an autoimmune disease?. Autoimmun Rev 2011, 10:756-761.
39. Fusconi M., Chistolini A., de Virgilio A., Greco A., Massaro F., Turchetta R., et al. Sudden sensorineural hearing loss: a vascular cause? Analysis of prothrombotic risk factors in head and neck. Int J Audiol 2012, 51:800-805.
40. Greco A., Gallo A., Fusconi M., Marinelli C., Macri G.F., de Vincentiis M. Bell's palsy and autoimmunity. Autoimmun Rev 2012, 12:323-328.
41. Keogh K.A., Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006, 27:148-157.
42. Masi A.T., Hunder G.G., Lie J.T., Michel B.A., Bloch D.A., Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33:1094-1100.
43. Szczeklik W., Sokolowska B., Mastalerz L., Grzanka P., Górka J., Pacułt K., et al. Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol 2010, 29:1127-1134.
44. Gupta S., Siddiqui S., Haldar P., Raj J.V., Entwisle J.J., Wardlaw A.J., et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009, 136:1521-1528.
45. Comarmond C., Pagnoux C., Khellaf M., Cordier J.F., Hamidou M., Viallard J.F., et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013, 65:270-281.
46. Moosig F., Bremer J.P., Hellmich B., Holle J.U., Holl-Ulrich K., Laudien M., et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013, 72:1011-1017.
47. Neumann T., Manger B., Schmid M., Kroegel C., Hansch A., Kaiser W.A., et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009, 88:236-243.
48. Bourgarit A., Le Toumelin P., Pagnoux C., Cohen P., Mahr A., Le Guern V., et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84:323-330.
49. Guillevin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90:19-27.
50. Dennert R.M., van Paassen P., Schalla S., Kuznetsova T., Alzand B.S., Staessen J.A., et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010, 62:627-634.
51. Vaglio A., Corradi D., Ronda N., Garini G., Buzio C. Large bowel obstruction heralding Churg-Strauss syndrome. Am J Gastroenterol 2004, 99:562-563.
52. Sironen R.K., Seppa A., Kosma V.M., Kuopio T. Churg-Strauss syndrome manifested by appendicitis, cholecystitis and superficial micronodular liver lesions-an unusual clinico pathological presentation. J Clin Pathol 2010, 63:848-850.
53. Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003, 115:284-290.
54. Sinico R.A., Di Toma L., Maggiore U., Tosoni C., Bottero P., Sabadini E., et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006, 47:770-779.
55. Sinico R.A., Di Toma L., Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 2013, 12:477-482.
56. Ramakrishna G., Midthun D.E. Churg-Strauss syndrome. Ann Allergy Asthma Immunol 2001, 86:603-613.
57. Marzano A.V., Vezzoli P., Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev 2013, 12:467-476.
58. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001, 14:1284-1293.
59. Zwerina J., Axmann R., Manger B., Schett G. The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum 2009, 60:626-627.
60. Conron M., Beynon H.L.C. Churg-Strauss syndrome. Thorax 2000, 55:870-877.
61. Lie J.T. Limited forms of Churg-Strauss syndrome. Pathol Annu 1993, 28(Pt 2):199-220.
62. Jennette J.C., Falk R.J. Small-vessel vasculitis. N Engl J Med 1997, 337:1512-1523.
63. Roufosse F.E., Goldam M., Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007, 2:37.
64. Corradi D., Vaglio A., Maestri R., Legname V., Leonardi G., Bartoloni G., et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol 2004, 35:1160-1163.
65. Mukhtyar C., Flossmann O., Hellmich B., Bacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis 2008, 67:1004-1010.
66. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss Syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
67. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Lauque D., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58:586-594.
68. Cohen P., Pagnoux C., Mahr A., Arene J.P., Mouthon L., Le Guern V., et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007, 57:686-693.
69. Solans R., Bosch J.A., Perez-Bocanegra C., Selva A., Huguet P., Alijotas J., et al. Churg Strauss syndrome: outcome and long term follow up of 32 patients. Rheumatology 2001, 40:763-771.
70. Holle J.U., Gross W.L. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev 2013, 12:483-486.
71. Pagnoux C., Guilpain P., Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007, 19:25-32.
72. Gayraud M., Guillevin L., Cohen P., Lhote F., Cacoub P., Deblois P., et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997, 35:1290-1297.
73. Danieli M.G., Cappelli M., Malcangi G., Logullo F., Salvi A., Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004, 63:1649-1654.
74. Tatsis E., Schnabel A., Gross W.L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998, 129:370-374.
75. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
76. Cartin-Ceba R., Keogh K.A., Specks U., Sethi S., Fervenza F.C. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011, 26:2865-2871.
77. Jones R.B., Ferraro A.J., Chaudhry A.N., Brogan P., Salama A.D., Smith K.G., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168.
78. Pepper R.J., Fabre M.A., Pavesio C., Gaskin G., Jones R.B., Jayne D., et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008, 47:1104-1105.
79. Winchester D.E., Jacob A., Murphy T. Omalizumab for asthma. N Engl J Med 2006, 355:1281-1282.
80. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
81. Giavina-Bianchi P., Giavina-Bianchi M., Agondi R., Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007, 144:155-158.
82. Josselin-Mahr L., Werbrouck-Chiraux A., Garderet L., Cabane J. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?. Rheumatology (Oxford) 2014, 53:378-379.